E-submission
Search
- Page Path
- HOME > Search
Original Articles
- Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers
- Jung Ho Kim, Jeong Mo Bae, Hyeon Jeong Oh, Hye Seung Lee, Gyeong Hoon Kang
- J Pathol Transl Med. 2015;49(2):118-128. Published online March 12, 2015
- DOI: https://doi.org/10.4132/jptm.2015.02.05
- 10,604 View
- 117 Download
- 18 Web of Science
- 14 Crossref
-
Abstract
PDF - Background
Although there are controversies regarding the benefit of fluoropyrimidine-based adjuvant chemotherapy in patients with microsatellite instability–high (MSI-H) colorectal cancer (CRC), the pathologic features affecting postchemotherapeutic prognosis in these patients have not been fully identified yet. Methods: A total of 26 histopathologic and immunohistochemical factors were comprehensively evaluated in 125 stage II or III MSI-H CRC patients who underwent curative resection followed by fluoropyrimidine-based adjuvant chemotherapy. We statistically analyzed the associations of these factors with disease-free survival (DFS). Results: Using a Kaplan- Meier analysis with log-rank test, we determined that ulceroinfiltrative gross type (p=.003), pT4 (p<.001), pN2 (p=.002), perineural invasion (p=.001), absence of peritumoral lymphoid reaction (p=.041), signet ring cell component (p=.006), and cribriform comedo component (p=.004) were significantly associated with worse DFS in patients receiving oxaliplatin-based adjuvant chemotherapy (n=45). By contrast, pT4 (p<.001) and tumor budding-positivity (p=.032) were significant predictors of poor survival in patients receiving non-oxaliplatin–based adjuvant chemotherapy (n=80). In Cox proportional hazards regression model-based univariate and multivariate analyses, pT category (pT1-3 vs pT4) was the only significant prognostic factor in patients receiving non-oxaliplatin–based adjuvant chemotherapy, whereas pT category, signet ring cell histology and cribriform comedo histology remained independent prognostic factors in patients receiving oxaliplatin-based adjuvant chemotherapy. Conclusions: pT4 status is the most significant pathologic determinant of poor outcome after fluoropyrimidine-based adjuvant chemotherapy in patients with stage II/III MSI-H CRC. -
Citations
Citations to this article as recorded by
- Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability
Alexander S Taylor, Natalia Liu, Jiayun M Fang, Nicole Panarelli, Lili Zhao, Jerome Cheng, Purva Gopal, Suntrea Hammer, Jing Sun, Henry Appelman, Maria Westerhoff
Journal of Clinical Pathology.2022; 75(7): 483. CrossRef - HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite Instability
Gaelle Tachon, Arnaud Chong-Si-Tsaon, Thierry Lecomte, Audelaure Junca, Éric Frouin, Elodie Miquelestorena-Standley, Julie Godet, Camille Evrard, Violaine Randrian, Romain Chautard, Marie-Luce Auriault, Valérie Moulin, Serge Guyetant, Gaelle Fromont, Luci
Frontiers in Genetics.2022;[Epub] CrossRef - Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma
Guang-Qian Xiao, Elise Nguyen, Pamela D. Unger, Andy E. Sherrod
Experimental and Molecular Pathology.2020; 114: 104400. CrossRef - Prognostic Predictability of American Joint Committee on Cancer 8th Staging System for Perihilar Cholangiocarcinoma: Limited Improvement Compared with the 7th Staging System
Jong Woo Lee, Jae Hoon Lee, Yejong Park, Woohyung Lee, Jaewoo Kwon, Ki Byung Song, Dae Wook Hwang, Song Cheol Kim
Cancer Research and Treatment.2020; 52(3): 886. CrossRef - Prognostic predictability of the new American Joint Committee on Cancer 8th staging system for distal bile duct cancer: limited usefulness compared with the 7th staging system
Jae Seung Kang, Seungyeoun Lee, Donghee Son, Youngmin Han, Kyung Bun Lee, Jae Ri Kim, Wooil Kwon, Sun‐Whe Kim, Jin‐Young Jang
Journal of Hepato-Biliary-Pancreatic Sciences.2018; 25(2): 124. CrossRef - Invasion Depth Measured in Millimeters is a Predictor of Survival in Patients with Distal Bile Duct Cancer: Decision Tree Approach
Kyueng‐Whan Min, Dong‐Hoon Kim, Byoung Kwan Son, Eun‐Kyung Kim, Sang Bong Ahn, Seong Hwan Kim, Yun Ju Jo, Young Sook Park, Jinwon Seo, Young Ha Oh, Sukjoong Oh, Ho Young Kim, Mi Jung Kwon, Soo Kee Min, Hye‐Rim Park, Ji‐Young Choe, Jang Yong Jeon, Hong Il
World Journal of Surgery.2017; 41(1): 232. CrossRef - BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-TypeBRAF-Expressing Cancer Independent of the Microsatellite Instability Status
Min Hye Jang, Sehun Kim, Dae Yong Hwang, Wook Youn Kim, So Dug Lim, Wan Seop Kim, Tea Sook Hwang, Hye Seung Han
Journal of Korean Medical Science.2017; 32(1): 38. CrossRef - Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma
Hye Eun Park, Jung Ho Kim, Nam-Yun Cho, Hye Seung Lee, Gyeong Hoon Kang
Virchows Archiv.2017; 471(3): 329. CrossRef - Dominant high expression of wild‐type HSP110 defines a poor prognostic subgroup of colorectal carcinomas with microsatellite instability: a whole‐section immunohistochemical analysis
Hyeon Jeong Oh, Jung Ho Kim, Tae Hun Lee, Hye Eun Park, Jeong Mo Bae, Hye Seung Lee, Gyeong Hoon Kang
APMIS.2017; 125(12): 1076. CrossRef - TNM Staging of Colorectal Cancer Should be Reconsidered According to Weighting of the T Stage
Jun Li, Cheng-Hao Yi, Ye-Ting Hu, Jin-Song Li, Ying Yuan, Su-Zhan Zhang, Shu Zheng, Ke-Feng Ding
Medicine.2016; 95(6): e2711. CrossRef - Molecular genetics of colorectal cancer
James Church
Seminars in Colon and Rectal Surgery.2016; 27(4): 172. CrossRef - Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers
Jung Ho Kim, Hye Eun Park, Nam-Yun Cho, Hye Seung Lee, Gyeong Hoon Kang
British Journal of Cancer.2016; 115(4): 490. CrossRef - Distinct features betweenMLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway
Jung Ho Kim, Jeong Mo Bae, Nam-Yun Cho, Gyeong Hoon Kang
Oncotarget.2016; 7(12): 14095. CrossRef - Tumor deposits: markers of poor prognosis in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy
Lu-Ning Zhang, Wei-Wei Xiao, Shao-Yan Xi, Pu-Yun OuYang, Kai-Yun You, Zhi-Fan Zeng, Pei-Rong Ding, Hui-Zhong Zhang, Zhi-Zhong Pan, Rui-Hua Xu, Yuan-Hong Gao
Oncotarget.2016; 7(5): 6335. CrossRef
- Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability
- ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC.
- Han Suk Ryu, Xianhua Xu, Hyojin Kim, Jong Suk Lee, Sanghoon Jheon, Jin Haeng Chung
- Korean J Pathol. 2011;45(1):45-52.
- DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.1.45
- 2,585 View
- 17 Download
-
Abstract
PDF
- BACKGROUND
The role of excision repair cross-complementation group 1 (ERCC1) has been controversial in non-small cell lung cancer (NSCLC) patients who received adjuvant chemotherapy with a platinum agent. We investigated ERCC1 expression in stage I-II NSCLC to clarify its significance for adjuvant chemotherapy.
METHODS
The ERCC1 expression profile was evaluated by immunohistochemistry and compared according to adjuvant chemotherapeutic agents in 146 patients who underwent surgical resection for stage I-II NSCLC. The patients were divided into 3 groups; adjuvant chemotherapy with a platinum based agent (18.5%, 27/146); adjuvant chemotherapy with uracil-tegafur (UFT) (40.4%, 59/146); surgery-alone (41.1%, 60/146).
RESULTS
Nuclear ERCC1 expression was detected in 71.9% (105/146) of NSCLC and was significantly associated with a shortened survival period in the group 1 patients who received the platinum based regimen after surgery. The group 2 patients who received UFT showed the longest survival period, followed by the surgery-alone group (overall survival, p=0.049; disease-free survival [DFS], p<0.001).
CONCLUSIONS
These results suggest that stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.
First
Prev
